Robert F. Kennedy Jr.'s nomination as Health Secretary has led to significant stock declines in vaccine and pharmaceutical companies. His history of vaccine skepticism raises concerns about regulatory changes and investment in the biotech sector, particularly affecting companies like Moderna and Pfizer.